Acute lymphoblastic leukaemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 121
• CD22 32
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

EU-13 is a filter, not a ranking: it only narrows the list.

19 of 19+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

  NCT03576547· M.D. Anderson Cancer Center· Updated 8 May 2025

  “The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

  NCT04530565· National Cancer Institute (NCI)· Source

• Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

  NCT07387926· Novartis Pharmaceuticals· Source

• Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

  2025-522019-40-00· Novartis Pharma AG· Source

• Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

  NCT07301424· University of Alberta· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• An Artificial Intelligence Framework for Detection of Leukemia with Comparison Between Segmented and Non-Segmented Images.

  Sensors (Basel), Oct 2026

• ClinNetDx: a novel explainable ai framework for acute lymphoblastic leukemia detection using multi-modal clinical data.

  BMC Cancer, Jul 2026

• Detection of acute lymphocytic and myeloid leukaemia with optimized dimensionality reduction and deep learning classification framework.

  Curr Res Transl Med, Jun 2026

• An explainable meta-learned hybrid CNN-transformer model with dual attention for leukemia diagnosis from peripheral blood smears.

  Sci Rep, Jun 2026

• A systematic review of machine and deep learning techniques for acute lymphoblastic leukemia diagnosis.

  Artif Intell Med, Mar 2026

• Improving acute lymphoblastic leukemia diagnosis through CBAM-enhanced VGG19 deep learning.

  Sci Rep, Feb 2026

• Reliable leukemia detection via transfer-enhanced Bayesian CNNs.

  Comput Biol Med, Jan 2026

• Blast cell segmentation and leukemia classification using hybrid Deep Kronecker WideResNet using blood smear images.

  Comput Biol Chem, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.